Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Read also

Teva wins FDA approval for Ponlimsi Prolia biosimilar in the U.S.

Teva received FDA approval for Ponlimsi, a Prolia biosimilar, while FDA and EMA accepted filings for its proposed Xolair biosimilar.

FDA fully approves Tecartus for relapsed or refractory mantle cell lymphoma

FDA granted full approval to Tecartus for adults with relapsed or refractory mantle cell lymphoma, expanding use beyond prior BTK inhibitor exposure.

Bio Solutions advances FDA codeine screening with fingerprint study

Intelligent Bio Solutions completed a fingerprint-based codeine screen study, supporting a planned FDA 510(k) submission for U.S. clearance.

Adagene and Incyte launch MSS colorectal cancer combination trial

Adagene and Incyte will start a Phase 1 trial in 2026 testing muzastotug with INCA33890 in third-line MSS colorectal cancer patients.